[HTML][HTML] The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib
VS Hoffmann, M Baccarani, D Lindörfer, F Castagnetti… - Leukemia, 2013 - nature.com
The introduction of tyrosine kinase inhibitors (TKI) in the treatment of Philadelphia
chromosome-positive (Ph+) chronic myeloid leukemia (CML) has revolutionized the …
chromosome-positive (Ph+) chronic myeloid leukemia (CML) has revolutionized the …
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with …
B Hanfstein, V Shlyakhto, M Lauseker, R Hehlmann… - Leukemia, 2014 - nature.com
Early assessment of response at 3 months of tyrosine kinase inhibitor treatment has become
an important tool to predict favorable outcome. We sought to investigate the impact of …
an important tool to predict favorable outcome. We sought to investigate the impact of …
[PDF][PDF] Молекулярная и цитогенетическая характеристика Ph-позитивного клона у больных хроническим миелолейкозом при длительном воздействии …
ОА Шухов - 2015 - blood.ru
Основным молекулярно-генетическим событием, приводящим к лейкемической
трансформации стволовых клеток и развитию хронического миелолекоза (ХМЛ) …
трансформации стволовых клеток и развитию хронического миелолекоза (ХМЛ) …
Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11–12, 2013
M Breccia, G Alimena, M Baccarani, M Bocchia… - Critical Reviews in …, 2014 - Elsevier
Abstract Treatment of Chronic Myeloid Leukaemia (CML) has evolved rapidly in the last 10
years. The objectives of this national consensus meeting were to describe the optimal …
years. The objectives of this national consensus meeting were to describe the optimal …
Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase
LP Akard, D Bixby - Leukemia & lymphoma, 2016 - Taylor & Francis
Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are available for the treatment of chronic
myeloid leukemia in chronic phase (CML-CP), and several baseline and on-treatment …
myeloid leukemia in chronic phase (CML-CP), and several baseline and on-treatment …
Valutazione del management del paziente affetto da leucemia mieloide cronica nella pratica clinica dell'Azienda ULSS 2 marca trevigiana, distretto di Treviso …
A Bettiol - 2018 - research.unipd.it
Introduction Chronic myeloid leukemia (CML) is a myelodysplastic neoplasia accounting for
around 15% of all cases of leukemia in adults. CML treatment is mainly based on tyrosine …
around 15% of all cases of leukemia in adults. CML treatment is mainly based on tyrosine …
[PDF][PDF] Молекулярная и цитогенетическая характеристика Ph-позитивного клона у больных хроническим миелолейкозом при длительном воздействии …
АГ Туркина - blood.ru
Основным молекулярно-генетическим событием, приводящим к лейкемической
трансформации стволовых клеток и развитию хронического миелолекоза (ХМЛ) …
трансформации стволовых клеток и развитию хронического миелолекоза (ХМЛ) …